
    
      To date we have studied 10 subjects who have followed through with all 3 of the original
      interventions (Placebo, 250 mg PeakATP/d and 400 mg PeakATP/d). Currently we have received
      approval and are expanding the study with 5 additional subjects who will receive the Placebo,
      400 mg PeakATP/d and the 400 mg PealATP/d plus proprietary blend interventions.
    
  